Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Challenger ( (AU:CGF) ) has provided an update.
Challenger Limited has notified the ASX that it and its associated entities have ceased to be substantial holders in Telix Pharmaceuticals, ending a previously disclosed significant shareholding position. The change, formally lodged via a statutory notice and signed by the company secretary, indicates a reduction in Challenger’s voting power in Telix and may reflect a reallocation of capital or a shift in portfolio strategy within its investment operations.
The filing confirms that Challenger’s relevant interest in Telix securities has fallen below the substantial holding threshold, although detailed transaction data is contained in annexures to the notice. For Telix and its shareholders, the move removes a large institutional investor from the register, potentially affecting the stock’s ownership structure and trading dynamics, while highlighting Challenger’s active management of its equity exposure.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.55 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
More about Challenger
Challenger Limited is an Australian financial services group based in Sydney, with operations and offices across major cities including Melbourne, Brisbane, Perth and Adelaide. Through various licensed subsidiaries, it is involved in retirement and investment services, life insurance, investment management, mortgage management and securitisation solutions for institutional and retail clients.
Average Trading Volume: 1,858,923
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$5.97B
See more data about CGF stock on TipRanks’ Stock Analysis page.